Phototherapy using methylene blue
US4950665A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Oct 28, 1988 |
| Grant date | Aug 21, 1990 |
| Priority date | — |
| Expiry date | Oct 28, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M1/3683
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is a method for using thiazin dyes, especially methylene blue, in combination with light to hydroxylate guanosine or deoxyguanosine at the C8 of the purine ring. The number of guanosines in a nucleic acid strand converted to 8-OH-deoxyguanosine (8-OH-dG) or 8-OH-guanosine (8-OH-G) can be controlled through manipulation of the concentration of methylene blue, light intensity and length of exposure, pH, and buffer strength. The method can be used for the selective mutation or modification of either a DNA or a RNA sequence, or the protein expressed therefrom. The method can also be used in the treatment of viral infectons and in cancer. Methylene blue is FDA approved for topical, i.v., and oral administration. Viruses, bacteria, and cells undergoing rapid DNA synthesis are all inactivated by methylene blue in the presence of light or when irradiated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.